2013 -- S 0454 SUBSTITUTE A

LC01023/SUB A

STATE OFRHODE ISLAND

IN GENERAL ASSEMBLY

JANUARY SESSION, A.D. 2013

AN ACT

RELATING TO FOOD AND DRUGS - UNIFORM CONTROLLED SUBSTANCES ACT

Introduced By: Senators Archambault, Cote, Lombardi, Conley, and Doyle

<u>Date Introduced:</u> February 28, 2013

Referred To: Senate Judiciary

It is enacted by the General Assembly as follows:

1 SECTION 1. Sections 21-28-1.0.2 and 21-28-2.0.8 of the General Laws in Chapter 21-28

2 entitled "Uniform Controlled Substances Act" are hereby amended to read as follows:

3 21-28-1.02. Definitions. -- Unless the context otherwise requires, the words and phrases as defined in this section are used in this chapter in the sense given them in the following 4

definitions:

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

(1) "Administer" refers to the direct application of controlled substances to the body of a patient or research subject by:

(i) A practitioner, or, in his or her presence by his or her authorized agent; or

(ii) The patient or research subject at the direction and in the presence of the practitioner whether the application is by injection, inhalation, ingestion, or any other means.

(2) "Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, wholesaler, distributor, or dispenser; except that these terms do not include a common or contract carrier or warehouse operator, when acting in the usual and lawful course of the carrier's or warehouse operator's business.

(3) "Apothecary" means a registered pharmacist as defined by the laws of this state and, where the context requires, the owner of a licensed pharmacy or other place of business where controlled substances are compounded or dispensed by a registered pharmacist; and includes registered assistant pharmacists as defined by existing law, but nothing in this chapter shall be construed as conferring on a person who is not registered as a pharmacist any authority, right, or

1 privilege that is not granted to him or her by the pharmacy laws of the state. 2 (4) "Automated data processing system" means a system utilizing computer software and 3 hardware for the purposes of record keeping. 4 (5) "Computer" means programmable electronic device capable of multi-functions, 5 including, but not limited to, storage, retrieval, and processing of information. (6) "Control" means to add a drug or other substance or immediate precursor to a 6 7 schedule under this chapter, whether by transfer from another schedule or otherwise. 8 (7) "Controlled substance" means a drug, substance, or immediate precursor, or synthetic 9 drug in schedules I -- V of this chapter. The term shall not include distilled spirits, wine, or malt 10 beverages, as those terms are defined or used in chapter 1 of title 3, nor tobacco. 11 (8) "Counterfeit substance" means a controlled substance which, or the container or 12 labeling of which, without authorization bears the trademark, trade name, or other identifying 13 mark, imprint, number, or device, or any likeness of them, of a manufacturer, distributor, or 14 dispenser, other than the person or persons who in fact manufactured, distributed, or dispensed 15 the substance and which thereby falsely purports or is represented to be the product of, or to have 16 been distributed by, the other manufacturer, distributor, or dispenser, or which substance is 17 falsely purported to be or represented to be one of the controlled substances by a manufacturer, 18 distributor, or dispenser. 19 (9) "CRT" means cathode ray tube used to impose visual information on a screen. 20 (10) "Deliver" or "delivery" means the actual, constructive, or attempted transfer of a 21 controlled substance or imitation controlled substance, whether or not there exists an agency 22 relationship. 23 (11) "Department" means the department of health of this state. 24 (12) "Depressant or stimulant drug" means: (i) A drug which contains any quantity of: 25 (A) Barbituric acid or derivatives, compounds, mixtures, or preparations of barbituric 26 27 acid; and 28 (B) "Barbiturate" or "barbiturates" includes all hypnotic and/or somnifacient drugs, 29 whether or not derivatives of barbituric acid, except that this definition shall not include bromides

amphetamine and/or desoxyephedrine, or any compound, mixture, or preparation of them.

(ii) A drug which contains any quantity of:

(A) Amphetamine or any of its optical isomers;

30

31

32

33

34

and narcotics.

(B) Any salt of amphetamine and/or desoxyephedrine or any salt of an optical isomer of

| 1 | (iii) A drug which contains any quantity of coca leaves. "Coca leaves" includes cocaine, |
|----|---|
| 2 | or any compound, manufacture, salt, derivative, mixture, or preparation of coca leaves, except |
| 3 | derivatives of coca leaves, which do not contain cocaine, ecgonine, or substance from which |
| 4 | cocaine or ecgonine may be synthesized or made. |
| 5 | (iv) Any other drug or substance which contains any quantity of a substance which the |
| 6 | attorney general of the United States, or the director of health, after investigation, has found to |
| 7 | have, or by regulation designates as having, a potential for abuse because of its depressant or |
| 8 | stimulant effect on the central nervous system. |
| 9 | (13) "Director" means the director of health. |
| 10 | (14) "Dispense" means to deliver, distribute, leave with, give away, or dispose of a |
| 11 | controlled substance to the ultimate user or human research subject by or pursuant to the lawful |
| 12 | order of a practitioner, including the packaging, labeling, or compounding necessary to prepare |
| 13 | the substance for that delivery. |
| 14 | (15) "Dispenser" is a practitioner who delivers a controlled substance to the ultimate user |
| 15 | or human research subject. |
| 16 | (16) "Distribute" means to deliver (other than by administering or dispensing) a |
| 17 | controlled substance or an imitation controlled substance and includes actual constructive, or |
| 18 | attempted transfer. "Distributor" means a person who so delivers a controlled substance or an |
| 19 | imitation controlled substance. |
| 20 | (17) "Downtime" means that period of time when a computer is not operable. |
| 21 | (18) "Drug addicted person" means a person who exhibits a maladaptive pattern of |
| 22 | behavior resulting from drug use, including one or more of the following: impaired control over |
| 23 | drug use; compulsive use; and/or continued use despite harm, and craving. |
| 24 | (19) "Drug Enforcement Administration" means the Drug Enforcement Administration |
| 25 | United States Department of Justice or its successor. |
| 26 | (20) "Federal law" means the Comprehensive Drug Abuse Prevention and Control Act of |
| 27 | 1970, (84 stat. 1236)(see generally 21 U.S.C. section 801 et seq.), and all regulations pertaining to |
| 28 | that federal act. |
| 29 | (21) "Hardware" means the fixed component parts of a computer. |
| 30 | (22) "Hospital" means an institution as defined in chapter 17 of title 23. |
| 31 | (23) "Imitation controlled substance" means a substance that is not a controlled |
| 32 | substance, which by dosage unit, appearance (including color, shape, size, and markings), or by |

representations made, would lead a reasonable person to believe that the substance is a controlled

substance and, which imitation controlled substances contain substances which if ingested, could

33

- be injurious to the health of a person. In those cases when the appearance of the dosage unit is not reasonably sufficient to establish that the substance is an "imitation controlled substance" (for example in the case of powder or liquid), the court or authority concerned should consider, in addition to all other logically relevant factors, the following factors as related to "representations made" in determining whether the substance is an "imitation controlled substance":

 (i) Statement made by an owner, possessor, transferor, recipient, or by anyone else in
 - (i) Statement made by an owner, possessor, transferor, recipient, or by anyone else in control of the substance concerning the nature of the substance, or its use or effect.
 - (ii) Statements made by the owner, possessor, or transferor, to the recipient that the substance may be resold for substantial profit.
 - (iii) Whether the substance is packaged in a manner reasonably similar to packaging of illicit controlled substances.
 - (iv) Whether the distribution or attempted distribution included an exchange of or demand for money or other property as consideration, and whether the amount of the consideration was substantially greater than the reasonable value of the non-controlled substance.
 - (24) "Immediate precursor" means a substance:

- (i) Which the director of health has found to be and by regulation designated as being the principal compound used, or produced primarily for use, in the manufacture of a controlled substance;
- (ii) Which is an immediate chemical intermediary used or likely to be used in the manufacture of those controlled substances; and
- (iii) The control of which is necessary to prevent, curtail, or limit the manufacture of that controlled substance.
- (25) "Laboratory" means a laboratory approved by the department of health as proper to be entrusted with controlled substances and the use of controlled substances for scientific and medical purposes and for the purposes of instruction.
- (26) "Marijuana" means all parts of the plant cannabis sativa L., whether growing or not; the seeds of the plant; the resin extracted from any part of the plant; and every compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seeds or resin, but shall not include the mature stalks of the plant, fiber produced from the stalks, oil or cake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture, or preparation of mature stalks, (except the resin extracted from it), fiber, oil or cake, or the sterilized seed from the plant which is incapable of germination.
- (27) "Manufacture" means the production, preparation, propagation, cultivation, compounding, or processing of a drug or other substance, including an imitation controlled

1 substance, either directly or indirectly or by extraction from substances of natural origin, or 2 independently by means of chemical synthesis or by a combination of extraction and chemical 3 synthesis and includes any packaging or repackaging of the substance or labeling or relabeling of 4 its container in conformity with the general laws of this state except by a practitioner as an 5 incident to his or her administration or dispensing of the drug or substance in the course of his or her professional practice. 6 7 (28) "Manufacturer" means a person who manufactures but does not include an 8 apothecary who compounds controlled substances to be sold or dispensed on prescriptions. 9 (29) "Narcotic drug" means any of the following, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical 10 11 synthesis or by a combination of extraction and chemical synthesis: 12 (i) Opium and opiates. 13 (ii) A compound, manufacture, salt, derivative, or preparation of opium or opiates. 14 (iii) A substance (and any compound, manufacture, salt, derivative, or preparation of it) 15 which is chemically identical with any of the substances referred to in paragraphs (i) and (ii) of 16 this subdivision. 17 (iv) Any other substance which the attorney general of the United States, or his or her 18 successor, or the director of health, after investigation, has found to have, and by regulation 19 designates as having, a potential for abuse similar to opium and opiates. 20 (30) "Official written order" means an order written on a form provided for that purpose 21 by the Drug Enforcement Administration under any laws of the United States making provision 22 for an official form, if order forms are authorized and required by federal law, and if no order 23 form is provided then on an official form provided for that purpose by the director of health. 24 (31) "Opiate" means any substance having an addiction-forming or addiction-sustaining 25 liability similar to morphine or being capable of conversion into a drug having addiction-forming 26 or addiction-sustaining liability. 27 (32) "Opium poppy" means the plant of the species papaver somniferum L., except the 28 seeds of the plant. 29 (33) "Ounce" means an avoirdupois ounce as applied to solids and semi-solids, and a 30 fluid ounce as applied to liquids. 31 (34) "Person" means any corporation, association, partnership, or one or more 32 individuals. 33 (35) "Physical dependence" means a state of adaptation that is manifested by a drug class specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, 34

| 2 | (36) "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing. |
|----|--|
| 3 | (37) "Practitioner" means: |
| 4 | (i) A physician, osteopath, dentist, chiropodist, veterinarian, scientific investigator, or |
| 5 | other person licensed, registered or permitted to distribute, dispense, conduct research with |
| 6 | respect to or to administer a controlled substance in the course of professional practice or research |
| 7 | in this state. |
| 8 | (ii) A pharmacy, hospital, or other institution licensed, registered or permitted to |
| 9 | distribute, dispense, conduct research with respect to, or to administer a controlled substance in |
| 10 | the course of professional practice or research in this state. |
| 11 | (38) "Printout" means a hard copy produced by computer that is readable without the aid |
| 12 | of any special device. |
| 13 | (39) "Production" includes the manufacture, planting, cultivation, growing, or harvesting |
| 14 | of a controlled substance. |
| 15 | (40) "Researcher" means a person authorized by the director of health to conduct a |
| 16 | laboratory as defined in this chapter. |
| 17 | (41) "Sell" includes sale, barter, gift, transfer, or delivery in any manner to another, or to |
| 18 | offer or agree to do the same. |
| 19 | (42) "Software" means programs, procedures and storage of required information data. |
| 20 | (43) "Synthetic drugs" means any synthetic cannabinoids or piperazines or any synthetic |
| 21 | cathinones as provided for in schedule I; |
| 22 | (44)(43) "Ultimate user" means a person who lawfully possesses a controlled substance |
| 23 | for his or her own use or for the use of a member of his or her household, or for administering to |
| 24 | an animal owned by him or her or by a member of his or her household. |
| 25 | (45)(44) "Wholesaler" means a person who sells, vends, or distributes at wholesale, or as |
| 26 | a jobber, broker agent, or distributor, or for resale in any manner in this state any controlled |
| 27 | substance. |
| 28 | 21-28-2.08. Contents of schedules Schedule I |
| 29 | (a) Schedule I shall consist of the drugs and other substances, by whatever official name, |
| 30 | common or usual name, chemical name, or brand name designated, listed in this section. |
| 31 | (b) Opiates Unless specifically excepted or unless listed in another schedule, any of |
| 32 | the following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and |
| 33 | ethers whenever the existence of the isomers, esters, ethers, and salts is possible within the |
| 34 | specific chemical designation: |

decreasing blood level of the drug, and/or administration of an antagonist.

| 1 | (1) Acetylmethadol |
|----|-----------------------------|
| 2 | (2) Allylprodine |
| 3 | (3) Alphacetylmethadol |
| 4 | (4) Alphameprodine |
| 5 | (5) Alphamethadol |
| 6 | (6) Benzethidine |
| 7 | (7) Betacetylmethadol |
| 8 | (8) Betameprodine |
| 9 | (9) Betamethadol |
| 10 | (10) Betaprodine |
| 11 | (11) Clonitazene |
| 12 | (12) Dextromoramide |
| 13 | (13) Difenoxin |
| 14 | (14) Diampromide |
| 15 | (15) Diethylthiambutene |
| 16 | (16) Dimenoxadol |
| 17 | (17) Dimepheptanol |
| 18 | (18) Dimethylthiambutene |
| 19 | (19) Dioxaphetyl butyrate |
| 20 | (20) Dipipanone |
| 21 | (21) Ethylmethylthiambutene |
| 22 | (22) Etonitazene |
| 23 | (23) Extoxerdine |
| 24 | (24) Furethidine |
| 25 | (25) Hydroxypethidine |
| 26 | (26) Ketobemidone |
| 27 | (27) Levomoramide |
| 28 | (28) Levophenacylmorphan |
| 29 | (29) Morpheridine |
| 30 | (30) Noracymethadol |
| 31 | (31) Norlevorphanol |
| 32 | (32) Normethadone |
| 33 | (33) Norpipanone |
| 34 | (34) Phenadoxone |
| | |

| 1 | (35) Phenampromide |
|----|--|
| 2 | (36) Phenomorphan |
| 3 | (37) Phenoperidine |
| 4 | (38) Piritramide |
| 5 | (39) Proheptazine |
| 6 | (40) Properidine |
| 7 | (41) Propiram |
| 8 | (42) Racemoramide |
| 9 | (43) Trimeperidone |
| 10 | (44) Tilidine |
| 11 | (45) Alpha-methylfentanyl |
| 12 | (46) Beta-hydroxy-3-methylfentanyl other names: |
| 13 | N-[1-(2hydroxy-2-phenethyl)-3-methyl-4piperidingyl] Nphenylpropanamide |
| 14 | (c) Opium Derivatives Unless specifically excepted or unless listed in anothe |
| 15 | schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers wheneve |
| 16 | the existence of the salts, isomers, and salts of isomers is possible within the specific chemical |
| 17 | designation: |
| 18 | (1) Acetorphine |
| 19 | (2) Acetyldihydrocodeine |
| 20 | (3) Benzylmorphine |
| 21 | (4) Codeine methylbromide |
| 22 | (5) Codeine-N-Oxide |
| 23 | (6) Cyprenorphine |
| 24 | (7) Desomorphine |
| 25 | (8) Dihydromorphine |
| 26 | (9) Etorphine (Except hydrochloride salt) |
| 27 | (10) Heroin |
| 28 | (11) Hydromorphinol |
| 29 | (12) Methyldesorphine |
| 30 | (13) Methylihydromorphine |
| 31 | (14) Morphine methylbromide |
| 32 | (15) Morphine methylsulfonate |
| 33 | (16) Morphine-N-Oxide |
| 34 | (17) Myrophine |

| 1 | (18) Nococodeine |
|----|--|
| 2 | (19) Nicomorphine |
| 3 | (20) Normorphine |
| 4 | (21) Pholcodine |
| 5 | (22) Thebacon |
| 6 | (23) Drotebanol |
| 7 | (d) Hallucinogenic Substances Unless specifically excepted or unless listed in another |
| 8 | schedule, any material, compound, mixture, or preparation, which contains any quantity of the |
| 9 | following hallucinogenic substances, or which contains any of its salts, isomers, and salts of |
| 10 | isomers whenever the existence of the salts, isomers, and salts of isomers is possible within the |
| 11 | specific chemical designation (for purposes of this subsection only, the term "isomer" includes |
| 12 | the optical, position, and geometric isomers): |
| 13 | (1) 3, 4-methylenedioxy amphetamine |
| 14 | (2) 5-methoxy-3, 4-methylenedioxy amphetamine |
| 15 | (3) 3, 4, 5-trimethoxy amphetamine |
| 16 | (4) Bufotenine |
| 17 | (5) Diethyltryptamine |
| 18 | (6) Dimethyltryptamine |
| 19 | (7) 4-methyl 2, 5-dimethoxyamphetamine |
| 20 | (8) Ibogaine |
| 21 | (9) Lysergic acid diethylamide |
| 22 | (10) Marihuana |
| 23 | (11) Mescaline |
| 24 | (12) Peyote. Meaning all parts of the plant presently classified botanically as |
| 25 | Lophophora Williamsii Lemair whether growing or not; the seeds of the plant; any extract from |
| 26 | any part of the plant; and any compound, manufacture, salt, derivative, mixture, or preparation of |
| 27 | the plant, its seeds or extracts. |
| 28 | (13) N-ethyl-3-piperidyl benzilate |
| 29 | (14) N-methyl-3-piperidyl benzilate |
| 30 | (15) Psilocybin |
| 31 | (16) Psilocyn |
| 32 | (17) Tetrahydrocannabinols. Synthetic equivalents of the substances contained in the |
| 33 | plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, and |
| 34 | their isomers with similar chemical structure and pharmacological activity such as the following: |

1 delta 1 cis or trans tetrahydrocannabinol, and their optical isomers. Delta 6 cis or trans 2 tetrahydrocannabinol and their optical isomers. Delta 3, 4 cis or trans tetrahydrocannabinol and 3 its optical isomer. (Since nomenclature of these substances is not internationally standardized, 4 compounds of these structures, regardless of numerical designation of atomic positions covered). 5 (18) Thiophene analog of phencyclidine. 1-(1-(2 thienyl) cyclo-hexyl) pipiridine: 2-Thienyl analog of phencyclidine: TPCP 6 7 (19) 2,5 dimethoxyamphetamine 8 4-bromo-2,5-dimethoxyamphetamine, 4-bromo-2,5-dimethoxy-alpha-9 methylphenethyamine: 4-bromo-2,5-DMA 10 4-methoxyamphetamine-4-methoxy-alpha-methylphenethylaimine: (21)11 paramethoxyamphetamine: PMA 12 (22) Ethylamine analog of phencyclidine. N-ethyl-1- phenylcyclohexylamine, (1-13 phenylcyclohexyl) ethylamine, N-(1-phenylcyclophexyl) ethylamine, cyclohexamine, PCE 14 (23) Pyrrolidine analog of phencyclidine. 1-(1-phencyclohexyl)- pyrrolidine PCPy, PHP (24) Parahexyl; some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-15 16 6,6,9-trimethyl-6H-dibenz o (b,d) pyran: Synhexyl. 17 (e) Depressants. - Unless specifically excepted or unless listed in another schedule, any 18 material, compound, mixture, or preparation which contains any quantity of the following 19 substances having a depressant effect on the central nervous system, including its salts, isomers, 20 and salts of isomers whenever the existence of the salts, isomers, and salts of isomers is possible 21 within the specific chemical designation: 22 (1) Mecloqualone. 23 (2) Methaqualone. 24 (3) 3-methyl fentanyl (n-(ethyl-1(2-phenylethyl)-4-piperidyl)-N-phenylpropanamide. 25 (4) 3,4-methyl-enedioxymethamphetamine (MDMA), its optical, positional and 26 geometric isomers, salts, and salts of isomers. 27 (5) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical isomers, salts and 28 salts of isomers. 29 (6) 1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine (PEPAP), its optical isomers, salts 30 and salts of isomers. 31 N-(1-(1-methyl-2-phenyl)ethyl-4-piperidyl)-N-phenyl-acetamide (acetyl-alpha-32 methylfentanyl), its optical isomers, salts and salts of isomers.

(8) N-(1-(1-methyl-2(2-thienyl)ethyl-4-piperidyl)-N-phenylpropanami

methylthiofentanyl), its optical isomers, salts and salts of isomers.

de (alpha-

33

| 1 | (9) N-(1-benzyl-piperidyl)-N-phenylpropanamide (benzyl-fentanyl), its optical isomers, |
|----|---|
| 2 | salts and salts of isomers. |
| 3 | (10) N-(1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl)-N-phenyl-propanamid e (beta- |
| 4 | hydroxyfentanyl), its optical isomers, salts and salts of isomers. |
| 5 | (11) N-(3-methyl-1(2-hydroxy-2-phenyl)ethyl-4-piperidyl)-N-phenylpro panamide (beta- |
| 6 | hydroxy-3-methylfentanyl), its optical and geometric isomers, salts and salts of isomers. |
| 7 | (12) N-(3-methyl)-1-(2-(2-thienyl)ethyl-4-piperidyl)-N-phenylpro- panamide (3- |
| 8 | methylthiofentanyl), its optical and geometric isomers, salts and salts of isomers. |
| 9 | (13) N-(1-2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its |
| 10 | optical isomers, salts and salts of isomers. |
| 11 | (14) N-(1-(2(2-thienyl)ethyl-4-piperidyl-N-phenylpropanamide (thiofentanyl), its optical |
| 12 | isomers, salts and salts of isomers. |
| 13 | (15) N-[1-(2-phenylethyl)-4-piperidyl]N-(4-fluorophenyl)-propanamid e (para- |
| 14 | fluorofentanyl), its optical isomers, salts and salts of isomers. |
| 15 | (16) Gamma hydroxybutyrate, HOOC-CH2-CH2-CH2OH, its optical, position, or |
| 16 | geometric isomers, salts and salts of isomers. |
| 17 | (f) Stimulants Unless specifically excepted or unless listed in another schedule, any |
| 18 | material, compound, mixture, or preparation which contains any quantity of the following |
| 19 | substances having a stimulant effect on the central nervous system, including its salts, isomers, |
| 20 | and salts of isomers: |
| 21 | (1) Fenethylline |
| 22 | (2) N-ethylamphetamine |
| 23 | (3) 4-methyl-N-methylcathinone (Other name: mephedrone) |
| 24 | (4) 3,4-methylenedioxy-N-methlycathinone (Other name: methylone) |
| 25 | (5) 3,4-methylenedioxypyrovalerone (Other name: MDPV) |
| 26 | (g) Any material, compound, mixture or preparation which contains any quantity of the |
| 27 | following substances: |
| 28 | (1) 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]phenol (CP-47,497) |
| 29 | (2) 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]phenol |
| 30 | (cannabicyclohexanol and CP-47,497 c8 homologue) |
| 31 | (3) 1-Butyl-3-(1 naphthoyl)indole, (JWH-073) |
| 32 | (4) 1-[2-(4-Morpholinyl)ethyl]3-(1-naphthoyl)indole (JWH-200) |
| 33 | (5) 1-Pentyl-3-(1-napthoyl)indole, (JWH-018 and AM678) |
| 34 | (b) Synthetic cannabinoids or piperazines. Unless specifically excepted, any chemical |

| 1 | compound which is not approved by the United States Food and Drug Administration or, if |
|----|--|
| 2 | approved, which is not dispensed or possessed in accordance with state and federal law, that |
| 3 | contains Benzylpiperazine (BZP); Trifluoromethylphenylpiperazine (TFMPP); 1,1- |
| 4 | Dimethylheptyl-11-hydroxytetrahydrocannabinol (HU-210); 1-Butyl-3-(1-naphthoyl)indole; 1- |
| 5 | Pentyl-3-(1-naphthoyl)indole; dexanabinol (HU-211); or any compound in the following |
| 6 | structural classes: |
| 7 | (1) Naphthoylindoles: Any compound containing a 3-(1-naphthoyl)indole structure with |
| 8 | substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, |
| 9 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
| 10 | group, whether or not further substituted in the indole ring to any extent and whether or not |
| 11 | substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not |
| 12 | limited, to JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, and AM- |
| 13 | <u>2201;</u> |
| 14 | (2) Phenylacetylindoles: Any compound containing a 3-phenylacetylindole structure with |
| 15 | substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, |
| 16 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
| 17 | group whether or not further substituted in the indole ring to any extent and whether or not |
| 18 | substituted in the phenyl ring to any extent. Examples of this structural class include, but are not |
| 19 | limited to, JWH-167, JWH-250, JWH-251, and RCS-8; |
| 20 | (3) Benzoylindoles: Any compound containing a 3-(benzoyl)indole structure with |
| 21 | substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, |
| 22 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
| 23 | group whether or not further substituted in the indole ring to any extent and whether or not |
| 24 | substituted in the phenyl ring to any extent. Examples of this structural class include, but are not |
| 25 | limited, to AM-630, AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; |
| 26 | (4) Cyclohexylphenols: Any compound containing a 2-(3-hydroxycyclohexyl)phenol |
| 27 | structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, |
| 28 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
| 29 | group whether or not substituted in the cyclohexyl ring to any extent. Examples of this structural |
| 30 | class include, but are not limited to, CP 47,497 and its C8 homologue (cannabicyclohexanol); |
| 31 | (5) Naphthylmethylindoles: Any compound containing a 1H-indol-3-yl-(1- |
| 32 | naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, |
| 33 | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4- |
| 34 | morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and |

| 1 | whether or not substituted in the naphthyl ring to any extent. Examples of this structural class |
|----|--|
| 2 | include, but are not limited to, JWH-175, JWH-184, and JWH-185; |
| 3 | (6) Naphthoylpyrroles: Any compound containing a 3-(1-naphthoyl)pyrrole structure |
| 4 | with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, |
| 5 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
| 6 | group whether or not further substituted in the pyrrole ring to any extent and whether or not |
| 7 | substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not |
| 8 | limited, to JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; |
| 9 | (7) Naphthylmethylindenes: Any compound containing a 1-(1-naphthylmethyl)indene |
| 10 | structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, |
| 11 | cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl |
| 12 | group whether or not further substituted in the indene ring to any extent and whether or not |
| 13 | substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not |
| 14 | limited to, JWH-176; or |
| 15 | (8) Any other synthetic cannabinoid or piperazine which is not approved by the United |
| 16 | States Food and Drug Administration or, if approved, which is not dispensed or possessed in |
| 17 | accordance with state and federal law; |
| 18 | (i) Synthetic cathinones. Unless specifically excepted, any chemical compound which is |
| 19 | not approved by the United States Food and Drug Administration or, if approved, which is not |
| 20 | dispensed or possessed in accordance with state and federal law, not including bupropion, |
| 21 | structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either |
| 22 | phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in |
| 23 | one or more of the following ways: |
| 24 | (1) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, |
| 25 | haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system |
| 26 | by one or more other univalent substituents. Examples of this class include, but are not limited to, |
| 27 | 3,4-Methylenedioxycathinone (bk-MDA); |
| 28 | (2) By substitution at the 3-position with an acyclic alkyl substituent. Examples of this |
| 29 | class include, but are not limited to, 2-methylamino-1-phenylbutan-1-one (buphedrone); |
| 30 | (3) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or |
| 31 | methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure. |
| 32 | Examples of this class include, but are not limited to, Dimethylcathinone, Ethcathinone, and α- |
| 33 | Pyrrolidinopropiophenone (α-PPP); or |
| 34 | (4) Any other synthetic cathinone which is not approved by the United States Food and |

| 1 | Drug Administration or, if approved, is not dispensed or possessed in accordance with state or |
|----|---|
| 2 | federal law; |
| 3 | Schedule II |
| 4 | (a) Schedule II shall consist of the drugs and other substances, by whatever official |
| 5 | name, common or usual name, chemical name, or brand name designated, listed in this section. |
| 6 | (b) Substances, vegetable origin or chemical synthesis Unless specifically excepted or |
| 7 | unless listed in another schedule, any of the following substances whether produced directly or |
| 8 | indirectly by extraction from substances of vegetable origin, or independently by means of |
| 9 | chemical synthesis, or by a combination of extraction and chemical synthesis: |
| 10 | (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or |
| 11 | opiate excluding naloxone and its salts, and excluding naltrexone and its salts, but including the |
| 12 | following: |
| 13 | (i) Raw opium |
| 14 | (ii) Opium extracts |
| 15 | (iii) Opium fluid extracts |
| 16 | (iv) Powdered opium |
| 17 | (v) Granulated opium |
| 18 | (vi) Tincture of opium |
| 19 | (vii) Etorphine hydrochloride |
| 20 | (viii) Codeine |
| 21 | (ix) Ethylmorphine |
| 22 | (x) Hydrocodone |
| 23 | (xi) Hydromorphone |
| 24 | (xii) Metopon |
| 25 | (xiii) Morphine |
| 26 | (xiv) Oxycodone |
| 27 | (xv) Oxymorphone |
| 28 | (xvi) Thebaine |
| 29 | (2) Any salt, compound, derivative, or preparation which is chemically equivalent or |
| 30 | identical with any of the substances referred to in subdivision (1) of this subsection, except that |
| 31 | these substances shall not include the isoquinoline alkaloids of opium. |
| 32 | (3) Opium poppy and poppy straw. |
| 33 | (4) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and |
| 34 | any salt, compound, derivative, or preparation which is chemically equivalent or identical with |

| 1 | any of these substances, except that the substances shall not include decocainized coca leaves or |
|----|--|
| 2 | extraction of coca leaves, which extractions do not contain cocaine or ecgonine. |
| 3 | (5) Concentrate of poppy straw (the crude extract of poppy straw in liquid, solid, or |
| 4 | powder form which contains the phenanthrine alkaloids of the opium poppy). |
| 5 | (c) Opiates Unless specifically excepted or unless listed in another schedule any of the |
| 6 | following opiates, including its isomers, esters, ethers, salts; and salts of isomers, esters and, |
| 7 | ethers whenever the existence of the isomers, esters, ethers, and salts is possible within the |
| 8 | specific chemical designation: |
| 9 | (1) Alphaprodine |
| 10 | (2) Anileridine |
| 11 | (3) Bezitramide |
| 12 | (4) Dihydrocodeine |
| 13 | (5) Diphenoxylate |
| 14 | (6) Fentanyl |
| 15 | (7) Isomethadone |
| 16 | (8) Levomethorphan |
| 17 | (9) Levorphanol |
| 18 | (10) Metazocine |
| 19 | (11) Methadone |
| 20 | (12) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane |
| 21 | (13) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic |
| 22 | acid |
| 23 | (14) Pethidine |
| 24 | (15) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine |
| 25 | (16) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate |
| 26 | (17) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid |
| 27 | (18) Phenaxocine |
| 28 | (19) Piminodine |
| 29 | (20) Racemethorphan |
| 30 | (21) Racemorphan |
| 31 | (22) Bulk Dextropropoxyphene (non-dosage forms) |
| 32 | (23) Suffentanil |
| 33 | (24) Alfentanil |
| 34 | (25) Levoalphacetylmethadol |

| 1 | (d) Stimulants Unless specifically excepted or unless listed in another schedule, any |
|----|---|
| 2 | material, compound, mixture, or preparation which contains any quantity of the following |
| 3 | substances having a stimulant effect on the central nervous system: |
| 4 | (1) Amphetamine, its salts, optical isomers, and salts of its optical isomers. |
| 5 | (2) Methamphetamine, its salts and salts of its isomers. |
| 6 | (3) Phenmetrazine and its salts. |
| 7 | (4) Methylphenidate. |
| 8 | (e) Depressants Unless specifically excepted or unless listed in another schedule, any |
| 9 | material, compound, mixture, or preparation which contains any quantity of the following |
| 10 | substances having a depressant effect on the central nervous system, including its salts, isomers, |
| 11 | and salts of isomers whenever the existence of the salts, isomers, and salts of isomers is possible |
| 12 | within the specific chemical designation: |
| 13 | (1) Amobarbital |
| 14 | (2) Glutethimide |
| 15 | (3) Methyprylon |
| 16 | (4) Pentobarbital |
| 17 | (5) Phencyclidine |
| 18 | (6) Secobarbital |
| 19 | (7) Phencyclidine immediate precursors: |
| 20 | (i) 1-phencyclohexylamine |
| 21 | (ii) 1-piperidinocyclohexane-carbonitrile (PCC) |
| 22 | (8) Immediate precursor to amphetamine and methamphetamine: Phenylacetone. Some |
| 23 | other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzone ketone. |
| 24 | Schedule III |
| 25 | (a) Unless specifically excepted or unless listed in another schedule, any material, |
| 26 | compound, mixture, or preparation which contains any quantity of the following substances |
| 27 | having a depressant effect on the central nervous system: |
| 28 | (1) Any substance which contains any quantity of a derivative of barbituric acid, or any |
| 29 | salt of a derivative of barbituric acid. |
| 30 | (2) Chlorhexadol |
| 31 | (3) Lysergic acid |
| 32 | (4) Lysergic acid amide |
| 33 | (5) Sulfondiethylmethane |
| 34 | (6) Sulfonethylmethane |

| 1 | (7) Sylfonmethane |
|----|--|
| 2 | (8) Any compound, mixture, or preparation containing amobarbital, secobarbital, |
| 3 | pentobarbital, or any salt of them and one or more other active medicinal ingredients which are |
| 4 | not listed in any schedule. |
| 5 | (9) Any suppository dosage form containing amobarbital, secobarbital, pentobarbital or |
| 6 | any salt of any of these drugs and approved by the Food and Drug Administration for marketing |
| 7 | only as a suppository. |
| 8 | (10) Ketamine, its salts, isomers and salts of isomers. (Some other names for ketamine: |
| 9 | (+)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone). |
| 10 | (b) Unless specifically excepted or unless listed in another schedule, any material, |
| 11 | compound, mixture, or preparation containing limited quantities of any of the following narcotic |
| 12 | drugs, or any salts of them: |
| 13 | (1) Not more than one and eight tenths grams (1.8 gms.) of codeine per one hundred |
| 14 | milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with an equal |
| 15 | or greater quantity of an isoquinoline alkaloid of opium. |
| 16 | (2) Not more than one and eight tenths grams (1.8 gms.) of codeine per one hundred |
| 17 | milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with one or |
| 18 | more active, nonnarcotic ingredients in recognized therapeutic amounts. |
| 19 | (3) Not more than three hundred milligrams (300 mgs.) of dihydrocodeinone per one |
| 20 | hundred milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with |
| 21 | a fourfold or greater quantity of an isoquinoline alkaloid of opium. |
| 22 | (4) Not more than three hundred milligrams (300 mgs.) of dihydrocodeinone per one |
| 23 | hundred milliliters (100 mls.) or not more than fifteen milligrams (15 mgs.) per dosage unit, with |
| 24 | one or more active nonnarcotic ingredients in recognized therapeutic amounts. |
| 25 | (5) Not more than one and eight tenths grams (1.8 gms.) of dihydrocodeine per one |
| 26 | hundred milliliters (100 mls.) or not more than ninety milligrams (90 mgs.) per dosage unit, with |
| 27 | one or more active nonnarcotic ingredients in recognized therapeutic amounts. |
| 28 | (6) Not more than three hundred milligrams (300 mgs.) of ethylmorphine per one |
| 9 | hundred milliliters (100 mls) or not more than fifteen millionams (15 mgs) per dosage unit with |

milliliters (100 mls.) or per one hundred grams (100 gms.) or not more than twenty-five

milligrams (25 mgs.) per dosage unit, with one or more active nonnarcotic ingredients in

(7) Not more than five hundred milligrams (500 mgs.) of opium per one hundred

one or more active nonnarcotic ingredients in recognized therapeutic amounts.

30

31

32

33

34

recognized therapeutic amounts.

| 1 | (8) Not more than fifty milligrams (50 mgs.) of morphine per one hundred milliliters |
|----|---|
| 2 | (100 mls.) per one hundred grams (100 gms.) with one or more active, nonnarcotic ingredients in |
| 3 | recognized therapeutic amounts. |
| 4 | (c) Stimulants Unless specifically excepted or listed in another schedule, any material, |
| 5 | compound, mixture, or preparation which contains any quantity of the following substances |
| 6 | having a stimulant effect on the central nervous system, including its salts, isomers, and salts of |
| 7 | the isomers whenever the existence of the salts of isomers is possible within the specific chemical |
| 8 | designation: |
| 9 | (1) Benzphetamine |
| 10 | (2) Chlorphentermine |
| 11 | (3) Clortermine |
| 12 | (4) Mazindol |
| 13 | (5) Phendimetrazine |
| 14 | (d) Steroids and hormones Anabolic steroids (AS) or human growth hormone (HGH), |
| 15 | excluding those compounds, mixtures, or preparations containing an anabolic steroid that because |
| 16 | of its concentration, preparation, mixture or delivery system, has no significant potential for |
| 17 | abuse, as published in 21 CFR 1308.34, including, but not limited to, the following: |
| 18 | (1) Chlorionic gonadotropin |
| 19 | (2) Clostebol |
| 20 | (3) Dehydrochlormethyltestosterone |
| 21 | (4) Ethylestrenol |
| 22 | (5) Fluoxymesterone |
| 23 | (6) Mesterolone |
| 24 | (7) Metenolone |
| 25 | (8) Methandienone |
| 26 | (9) Methandrostenolone |
| 27 | (10) Methyltestosterone |
| 28 | (11) Nandrolone decanoate |
| 29 | (12) Nandrolone phenpropionate |
| 30 | (13) Norethandrolone |
| 31 | (14) Oxandrolone |
| 32 | (15) Oxymesterone |
| 33 | (16) Oxymetholone |
| 34 | (17) Stanozolol |

| 1 | (18) Testosterone propionate |
|----|---|
| 2 | (19) Testosterone-like related compounds |
| 3 | (20) Human Growth Hormone (HGH) |
| 4 | (e) Hallucinogenic substances. |
| 5 | (1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in |
| 6 | U.S. Food and Drug Administration approved drug product. (Some other names for dronabinol: |
| 7 | (6aR-trans)-6a, 7, 8, 10a- tetrahydro-6, 6, 9- trimethyl-3-pentyl-6H- dibenzo[b,d]yra n-1-ol,or(-)- |
| 8 | delta-9(trans)-tetrahydrocannabinol.) |
| 9 | Schedule IV |
| 10 | (1) Barbital. |
| 11 | (2) Chloral betaine |
| 12 | (3) Chloral hydrate |
| 13 | (4) Ethchrovynol |
| 14 | (5) Ethinamate |
| 15 | (6) Methohexital |
| 16 | (7) Meprobamate |
| 17 | (8) Methylphenobarbital |
| 18 | (9) Paraldehyde |
| 19 | (10) Petrichloral |
| 20 | (11) Phenobarbital |
| 21 | (12) Fenfluramine |
| 22 | (13) Diethylpropion |
| 23 | (14) Phentermine |
| 24 | (15) Pemoline (including organometallic complexes and chelates thereof). |
| 25 | (16) Chlordiazepoxide |
| 26 | (17) Clonazepam |
| 27 | (18) Clorazepate |
| 28 | (19) Diazepam |
| 29 | (20) Flurazepam |
| 30 | (21) Mebutamate |
| 31 | (22) Oxazepam |
| 32 | (23) Unless specifically excepted or unless listed in another schedule, any material, |
| 33 | compound, mixture, or preparation which contains any quantity of the following substances, |
| 34 | including its salts: |

| 1 | Dextropropoxyphene(alpha-(+)-4-dimethylamino-1,2-diphenyl-3- methyl-2- |
|----|--|
| 2 | propronoxybutane). |
| 3 | (24) Prazepam |
| 4 | (25) Lorazepam |
| 5 | (26) Not more than one milligram (1 mg.) of difenoxin and not less than twenty-five (25) |
| 6 | micrograms of atropine sulfate per dosage unit. |
| 7 | (27) Pentazocine |
| 8 | (28) Pipradrol |
| 9 | (29) SPA (-)-1-dimethylamino-1, 2-diphenylethane |
| 10 | (30) Temazepam |
| 11 | (31) Halazepam |
| 12 | (32) Alprazolam |
| 13 | (33) Bromazepam |
| 14 | (34) Camazepam |
| 15 | (35) Clobazam |
| 16 | (36) Clotiazepam |
| 17 | (37) Cloxazolam |
| 18 | (38) Delorazepam |
| 19 | (39) Estazolam |
| 20 | (40) Ethyl Ioflazepate |
| 21 | (41) Fludizaepam |
| 22 | (42) Flunitrazepam |
| 23 | (43) Haloxazolam |
| 24 | (44) Ketazolam |
| 25 | (45) Loprazolam |
| 26 | (46) Lormetazepam |
| 27 | (47) Medazepam |
| 28 | (48) Nimetazepam |
| 29 | (49) Nitrazepam |
| 30 | (50) Nordiazepam |
| 31 | (51) Oxazolam |
| 32 | (52) Pinazepam |
| 33 | (53) Tetrazepam |
| 34 | (54) Mazindol |

| 1 | (55) Triazolam |
|----|--|
| 2 | (56) Midazolam |
| 3 | (57) Quazepam |
| 4 | (58) Butorphanol |
| 5 | (59) Sibutramine |
| 6 | Schedule V |
| 7 | (a) Any compound, mixture, or preparation containing any of the following limited |
| 8 | quantities of narcotic drugs, which shall include one or more non-narcotic active medicinal |
| 9 | ingredients in sufficient proportion to confer upon the compound, mixture, or preparation |
| 10 | valuable medicinal qualities other than those possessed by the narcotic drug alone: |
| 11 | (1) Not more than two hundred milligrams (200 mgs.) of codeine per 100 milliliters (100 |
| 12 | mls.) or per one hundred grams (100 gms.). |
| 13 | (2) Not more than one hundred milligrams (100 mgs.) of dihydrocodeine per 100 |
| 14 | milliliters (100 mls.) or per one hundred grams (100 gms.). |
| 15 | (3) Not more than one hundred milligrams (100 mgs.) of ethylmorphine per 100 |
| 16 | milliliters (100 mls.) or per one hundred grams (100 gms.). |
| 17 | (4) Not more than two and five tenths milligrams (2.5 mgs.) of diphenixylate and not less |
| 18 | than twenty-five (25) micrograms of atropine sulfate per dosage unit. |
| 19 | (5) Not more than one hundred milligrams (100 mgs.) of opium per one hundred |
| 20 | milliliters (100 mls.) or per one hundred grams (100 gms.). |
| 21 | (b) Not more than five tenths milligrams (0.5 mgs.) of difenoxin and not less than |
| 22 | twenty-five (25) micrograms of atropine sulfate per dosage unit. |
| 23 | (c) Buprenorphine |
| 24 | (d) Unless specifically exempted or excluded or unless listed in another schedule, any |
| 25 | material, compound, mixture, or preparation which contains any quantity of the following |
| 26 | substances having a stimulant effect on the central nervous system, including its salts, isomers |
| 27 | and salts of isomers: |
| 28 | (1) Propylhexedrine (except as benzedrex inhaler) |
| 29 | (2) Pyrovalerone. |
| 30 | SECTION 2. This act shall take effect upon passage. |
| | |

LC01023/SUB A

EXPLANATION

BY THE LEGISLATIVE COUNCIL

OF

AN ACT

RELATING TO FOOD AND DRUGS - UNIFORM CONTROLLED SUBSTANCES ACT

This act would add the chemical classes of synthetic cannaboids and synthetic cathinones
to Schedule I.

This act would take effect upon passage.

LC01023/SUB A